CAR-T & Cellular Therapy Focus

Explore the latest updates and expert interviews

The CAR-T & Cellular Therapy Focus on VJHemOnc is supported by Janssen Pharmaceuticals (a Johnson & Johnson Company) and Legend Biotech. These supporters have no influence over the production of the content.

Welcome to CAR-T & Cellular Therapy Focus

Explore the latest updates in this field by haematological disease and therapy type, showcasing expert interviews and discussions, podcasts and e-learning.

CAR-T and other cellular therapies are at the frontier of hematological malignancy research, offering the potential for paradigm-changing new treatments. Although various questions remain open, it is essential that healthcare professionals understand these therapies, including recognizing and managing their toxicities, and when and how to use them.

Latest CAR-T and Cellular Therapy Videos

View all
2:43
Long-term follow-up results of ZUMA-5: axicabtagene ciloleucel in patients with R/R indolent NHL
Sattva Neelapu • 12 Dec 2021
4:28
Efficacy of anti-myeloma therapies following relapse on idecabtagene vicleucel
Nikhil Munshi • 14 Dec 2021
2:17
ZUMA-12: axicabtagene ciloleucel as a first-line therapy in patients with high-risk LBCL
Sattva Neelapu • 12 Dec 2021
9:25
Improving MDS management: new targets, drug combinations, and personalized and cellular therapies
Andrew M. Brunner et al. • 11 Dec 2021

View CAR-T and Cellular Therapy Videos by Disease Area

Multiple Myeloma
Lymphoma
ALL
AML
CLL
4:28
Efficacy of anti-myeloma therapies following relapse on idecabtagene vicleucel
Nikhil Munshi • 14 Dec 2021
4:33
Cilta-cel elicits deep and durable responses in patients with multiple myeloma with early relapse
Niels van de Donk • 13 Dec 2021
3:03
The future of CAR-T therapy for multiple myeloma
Niels van de Donk • 13 Dec 2021
1:54
Myeloma highlights: UK perspective
Charlotte Pawlyn • 13 Dec 2021
View All Videos
2:43
Long-term follow-up results of ZUMA-5: axicabtagene ciloleucel in patients with R/R indolent NHL
Sattva Neelapu • 12 Dec 2021
2:17
ZUMA-12: axicabtagene ciloleucel as a first-line therapy in patients with high-risk LBCL
Sattva Neelapu • 12 Dec 2021
3:08
Updates in CAR-T for non-Hodgkin lymphoma
Graham Collins • 15 Dec 2021
3:19
Updates in CAR-T for non-Hodgkin lymphoma
Graham Collins • 15 Dec 2021
View All Videos
2:41
PBCAR0191, an allogeneic CAR T-cell therapy, in B-ALL
Nitin Jain • 13 Dec 2021
1:43
UCART22 in B-ALL: Preliminary results from the BALLI-01 trial
Nitin Jain • 13 Dec 2021
2:30
CAR-T cell therapies in T-cell lymphoma and leukemia
LaQuisa Hill • 13 Dec 2021
0:49
Gilteritinib and CAR T-cell therapy in high-risk pediatric leukemias
Sarah Tasian • 13 Dec 2021
View All Videos
0:49
Gilteritinib and CAR T-cell therapy in high-risk pediatric leukemias
Sarah Tasian • 13 Dec 2021
1:57
GTB-3550 TriKE for the treatment of MDS & AML
Jeffrey S. Miller • 12 Nov 2021
1:48
Mechanism of action of GTB-3550 TriKE
Jeffrey S. Miller • 12 Nov 2021
1:27
Future prospects for NK cell therapy
Jeffrey S. Miller • 12 Nov 2021
View All Videos
1:28
The future of CLL treatment
Paolo Ghia • 13 Dec 2021
2:18
Advancements within the CLL treatment landscape
Jacqueline Barrientos • 13 Dec 2021
2:22
Epcore CLL-1: phase III trial of epcoritamab in r/r CLL
Arnon Kater • 10 Dec 2021
1:09
CAR-T for CLL
Kerry Rogers • 10 Dec 2021
View All Videos

Features

View all
Brexucabtagene autoleucel receives FDA approval for R/R B-ALL
IMW 2021: Heinz Ludwig and Hermann Einsele discuss meeting highlights
IMW 2021: myeloma updates with Maria-Victoria Mateos and Irene Ghobrial
Key trial updates from IMW 2021

View CAR-T and Cellular Therapy Videos by Topic

Nursing
Clinical Practice
Policy
Treatment
Toxicity
Manufacturing
1:13
CAR-T nursing education
Erik Aerts • 4 Feb 2021
1:08
CAR-T therapy: treatment burden and costs
Erik Aerts • 4 Feb 2021
1:26
Highlights from the nurses program
Erik Aerts • 4 Feb 2021
0:46
Nursing sessions: what to look for at EBMT 2020
John Murray • 30 Jan 2020
View All Videos
9:25
Improving MDS management: new targets, drug combinations, and personalized and cellular therapies
Andrew M. Brunner et al. • 11 Dec 2021
2:17
Update on TRANSFORM: liso-cel vs SOC in R/R LBCL
Manali Kamdar • 14 Dec 2021
2:09
The financial burden of CAR T-cell therapy
Surbhi Sidana • 14 Dec 2021
1:58
Patient-reported outcomes vs performance-based metrics: the effects of CAR-T therapy on cognition
Surbhi Sidana • 14 Dec 2021
View All Videos
6:22
Current challenges faced with CAR T-cell therapies
Christian Chabannon • 22 Sep 2021
1:40
Regulatory considerations for CAR-T academic trials
Manel Juan Otero • 25 Jan 2021
1:43
Collaboration in the field of cellular therapies
Sofie Terwel • 28 Jan 2021
0:44
CAR-T regulatory issues and reimbursements
Jürgen Kuball • 27 Jan 2021
View All Videos
2:43
Long-term follow-up results of ZUMA-5: axicabtagene ciloleucel in patients with R/R indolent NHL
Sattva Neelapu • 12 Dec 2021
4:28
Efficacy of anti-myeloma therapies following relapse on idecabtagene vicleucel
Nikhil Munshi • 14 Dec 2021
2:17
ZUMA-12: axicabtagene ciloleucel as a first-line therapy in patients with high-risk LBCL
Sattva Neelapu • 12 Dec 2021
9:25
Improving MDS management: new targets, drug combinations, and personalized and cellular therapies
Andrew M. Brunner et al. • 11 Dec 2021
View All Videos
2:43
Long-term follow-up results of ZUMA-5: axicabtagene ciloleucel in patients with R/R indolent NHL
Sattva Neelapu • 12 Dec 2021
1:28
Assessment of CAR-T and TCR adverse events
Cecilia Yeung • 13 Nov 2021
3:21
Practical considerations for CAR-T therapy in lymphoma
Ulrich Jäger • 18 Jun 2021
4:12
Opportunities to improve CAR-T outcomes
Jordan Gauthier • 30 Mar 2020
View All Videos
3:51
Donor-derived allogeneic CAR-T for B-ALL post-transplant
Claire Roddie • 7 Dec 2019
1:31
The importance of the European Medicines Agency in CAR-T development
Ulrich Jäger
11:58
iwNHL day 2 highlights: bridging the gap to CAR T-cell therapy & precision medicine
Anas Younes et al. • 22 Sep 2018
3:08
Identifying patient subgroups to improve outcome, resistance and toxicity in CAR T
John Rossi • 12 Sep 2018
View All Videos

Podcasts

View all
COSTEM: the role of alloHSCT in ALL
IACH 2021: CAR-T in clinical practice
CAR-T vs bispecifics: replacing ASCT in myeloma
EHA 2021: targeted therapies for ALL

View CAR-T and Cellular Therapy Videos by Therapy Type

CAR T-Cell Therapy
NK-Cell Therapy
2:43
Long-term follow-up results of ZUMA-5: axicabtagene ciloleucel in patients with R/R indolent NHL
Sattva Neelapu • 12 Dec 2021
2:17
ZUMA-12: axicabtagene ciloleucel as a first-line therapy in patients with high-risk LBCL
Sattva Neelapu • 12 Dec 2021
3:08
Updates in CAR-T for non-Hodgkin lymphoma
Graham Collins • 15 Dec 2021
4:33
Cilta-cel elicits deep and durable responses in patients with multiple myeloma with early relapse
Niels van de Donk • 13 Dec 2021
View All Videos
1:14
NK cells in hematological malignancies
Krish Patel • 13 Dec 2021
1:04
FT516: A novel NK cell therapy targeting B-cell lymphoma
Krish Patel • 13 Dec 2021
1:34
NK-CAR immunotherapy: where are we now?
Concetta Quintarelli • 4 Feb 2021
2:39
What are the next steps for CAR-T in myeloma?
Sham Mailankody • 8 Dec 2020
View All Videos

The CAR-T & Cellular Therapy Focus on VJHemOnc is supported by Janssen Pharmaceuticals (a Johnson & Johnson Company) and Legend Biotech.

These supporters have no influence over the production of the content.

If you are interested in becoming a supporter of The CAR-T & Cellular Therapy Focus, please contact us.

VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals